Baudax Bio

Baudax Bio, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of products for acute care settings. The company was founded in 2015 and is headquartered in Malvern, PA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Effective October 1, 2020, New Code Expected to Expand Reimbursement Effective October 1, 2020, New Code Expected to Expand Reimbursement

Baudax Bio Secures Permanent J-Code (J1738) for ANJESO® from Centers for Medicare and Medicaid Services

Virtual Presentation Highlights New ANJESO Clinical Results, Including Safety, Reductions in Opioid Use and Time to Bowel Function Recovery Data When Administered Preoperatively Prior to Colorectal Surgery Virtual Presentation Highlights New ANJESO Clinical Results, Including Safety, Reductions in Opioid Use and Time to Bowel Function Recovery Data When Administered Preoperatively Prior to Colorectal Surgery 

Baudax Bio Announces Presentation of New Phase IIIb ANJESO® Data at the American Society of Colon and Rectal Surgeons 2020 Annual Scientific Meeting

MALVERN, Pa., July  20, 2020  (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it has entered into a Pharmacy Supplier Agreement with Vizient, Inc. effective as of July 1, 2020, to offer ANJESO (meloxicam) injection, a non-opioid option for managing moderate to severe pain. The agreement offers enhanced savings to Vizient’s diverse membership, which includes more than 50% of the nation’s acute care providers, including 95% of the nation’s academic medical centers, and more than 20% of ambulatory care providers.

Baudax Bio Secures Pharmacy Supplier Agreement with Vizient Inc. for ANJESO®

ANJESO Is The Only Approved 24-Hour, Intravenous COX-2 Preferential NSAID that Offers Once-Daily Dosing ANJESO Is The Only Approved 24-Hour, Intravenous COX-2 Preferential NSAID that Offers Once-Daily Dosing

Baudax Bio Announces Full Commercial Launch of ANJESO™ and Receipt of Unique C-Code and Pass-Through Payment Status Effective July 1, 2020

MALVERN, Pa., June  01, 2020  (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it has closed on a credit facility of up to $50 million from funds managed by Marathon Asset Management, a global credit solutions partner. Proceeds from the facility will generally be used to support the commercial launch of ANJESOTM (meloxicam) injection, and for working capital purposes.  JMP Securities LLC acted as exclusive financial advisor and sole placement agent to Baudax on this transaction.

Baudax Bio Secures $50 Million Credit Facility

Baudax Bio, Inc. (BXRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

All You Need to Know About Baudax Bio, Inc. (BXRX) Rating Upgrade to Buy

  ANJESO™ Approved by FDA for the Management of Moderate to Severe Pain; Product Now Available for Ordering and Delivery for Customers

Baudax Bio Reports First Quarter 2020 Financial Results

Virtual Presentation Highlights New ANJESO Health Resource Utilization Data When Administered Preoperatively in Colorectal Surgery as Part of a Multimodal Analgesia Regimen Virtual Presentation Highlights New ANJESO Health Resource Utilization Data When Administered Preoperatively in Colorectal Surgery as Part of a Multimodal Analgesia Regimen

Baudax Bio Announces Presentation of New Phase IIIb ANJESO™ Data at Digestive Disease Week 2020

Baudax Bio, Inc. (BXRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Baudax Bio, Inc. (BXRX) Upgraded to Buy: Here's What You Should Know

MALVERN, Pa., April  03, 2020  (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that the Compensation Committee of Baudax Bio’s Board of Directors approved inducement grants of stock options to purchase an aggregate of 182,187 shares of Baudax Bio’s common stock and restricted stock units covering 56,384 shares of Baudax Bio’s common stock to 17 newly-hired employees, with a grant date of March 31, 2020.  The equity awards were granted pursuant to the NASDAQ Rule 5635(c)(4) inducement grant exception as a component of each individual’s employment compensation and were granted as an inducement material to his or her acceptance of employment with Baudax Bio.

Baudax Bio Reports Inducement Grants Under Nasdaq  Listing Rule 5635(c)(4)

MALVERN, Pa., March  26, 2020  (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (“Baudax” or the “Company”) (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the closing of the previously announced public offering, reflective of 7,692,308 shares of its common stock, Series A Warrants to purchase 7,692,308 shares of common stock and Series B Warrants to purchase 7,692,308 shares of common stock, at an exercise price of $4.59 per share for Series A Warrants and at an exercise price of $3.25 per share for Series B Warrants. Each share of common stock was sold together with one Series A warrant and one Series B warrant for a combined price of $3.25 per share, for gross proceeds of $25 million, not including any future proceeds from the exercise of the Series A warrants and Series B warrants and before deducting the underwriting discounts and commissions and offering expenses. The shares of common stock, Series A warrants and Series B warrants were purchased together but were issued separately and are immediately separable upon issuance.

Baudax Bio Announces Closing of $25 Million Public Offering of Securities

MALVERN, Pa., March  24, 2020  (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (“Baudax” or the “Company”) (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the pricing of an underwritten public offering of 7,692,308 shares of its common stock, Series A warrants to purchase 7,692,308 shares of common stock and Series B warrants to purchase 7,692,308 shares of common stock, at an exercise price of $4.59 per share for Series A Warrants and at an exercise price of $3.25 per share for Series B Warrants. Each share of common stock is being sold together with one Series A warrant and one Series B warrant for a combined price of $3.25 per share, for a gross offering size of $25 million, not including any future proceeds from the exercise of the Series A warrants and Series B warrants and before deducting the underwriting discounts and commissions and offering expenses. The shares of common stock, Series A warrants and Series B warrants can only be purchased together but will be issued separately and will be immediately separable upon issuance.

Baudax Bio Announces Pricing of Public Offering of Common Stock and Warrants

MALVERN, Pa., March  23, 2020  (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (“Baudax” or the “Company”) (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it has commenced an underwritten public offering of its common stock, Series A warrants and Series B warrants.  All of the securities in the offering are to be sold by Baudax.

Baudax Bio Announces Proposed Public Offering of Common Stock and Warrants

Strategic Financing to Provide Funding for the Commercial Launch of ANJESO™ Strategic Financing to Provide Funding for the Commercial Launch of ANJESO™

Baudax Bio Signs Non-Binding Term Sheet for Debt Facility

Tiny, Underfollowed Baudax Bio Way Too Cheap After Receiving FDA Drug Approval

Baudax Bio (BXRX) news for Friday surrounding approval from the U.S. Food & Drug Administration has BXRX stock taking off.

Baudax Bio News: BXRX Stock Soars 15% on FDA Drug Approval

Baudax Bio is a recent spin-out of Recro Pharma's Acute Care Segment and is already preparing for Ajenso's PDUFA date on February 20th.

Baudax Bio: Recro's Spin-Out Is A Buy At These Prices

PDUFA Goal Date Set for February 20, 2020 PDUFA Goal Date Set for February 20, 2020

Baudax Bio Announces PDUFA Date for Intravenous Meloxicam

News for Baudax Bio Stock (BXRX)